The Ontario Securities Commission (OSC) granted Fusion Pharmaceuticals Inc.’s application to cease being a reporting issuer in all Canadian jurisdictions. This decision was made under the authority of the Securities Act, R.S.O. 1990, c. S.5, as amended, specifically section 1(10)(a)(ii). The application was processed under National Policy 11-206 and Multilateral Instrument 11-102, with the OSC acting as the principal regulator. Fusion Pharmaceuticals met the criteria for this order, including having fewer than 15 securityholders in each Canadian jurisdiction and fewer than 51 worldwide, no securities traded on public marketplaces, and no defaults on securities legislation. Consequently, the OSC concluded that the order was justified and granted it.
Fusion Pharmaceuticals Inc.
June 14, 2024 | Order | Securities Act | Issuers | https://www.osc.ca/en/securities-law/orders-rulings-decisions/fusion-pharmaceuticals-inc
: Securities Act, R.S.O. 1990, c. S.5, as am., s. 1(10)(a)(ii).
CAUTION: Lexata's content was last updated in 2024 and may not reflect current securities regulatory requirements.